Acute Kidney Injury (AKI) Market to Observe Stupendous Growth During the Forecast Period (2022-32) – DelveInsight | Key Companies – Alloksys, Angion, AM Pharma, AtoxBio, Astellas, Pharming, MediBeacon 1
Acute Kidney Injury (AKI) Market to Observe Stupendous Growth During the Forecast Period (2022-32) - DelveInsight | Key Companies - Alloksys, Angion, AM Pharma, AtoxBio, Astellas, Pharming, MediBeacon
Delveinsight Business Research LLP
The Acute Kidney Injury market size in the 7MM was USD 5,208 million in 2021 and is projected to rise in the coming years. As per DelveInsight, the Acute Kidney Injury (AKI) Therapeutics Market dynamics are expected to transform owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment.

Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat/improve the disease.

DelveInsight’s “Acute Kidney Injury (AKI) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Kidney Injury market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Acute Kidney Injury market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Kidney Injury (AKI) Market to Observe Stupendous Growth During the Forecast Period (2022-32) – DelveInsight | Key Companies – Alloksys, Angion, AM Pharma, AtoxBio, Astellas, Pharming, MediBeacon 2

Acute Kidney Injury (AKI): An Overview

Acute Renal Failure (ARF), which is now known as Acute Kidney Injury, is characterized by azotemia that progresses over several hours or days, with or without oliguria. ARF is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to the abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.

Patient history and physical examination, with an emphasis on assessing the patient’s volume status, are crucial for determining the cause of acute kidney injury. Supportive therapies (e.g., antibiotics, maintenance of adequate nutrition, mechanical ventilation, glycemic control, and anemia management) should be pursued based on standard management practices.

Acute Kidney Injury (AKI) Market Key Facts

  • The Acute Kidney Injury market size in the 7MM is USD 5,208 million in 2021 and is projected to grow during the forecast period (2022-2032).

  • According to the estimates, the largest Acute Kidney Injury market size is from the United States, in 2021 and is anticipated to grow at a CAGR of 3.7%.

  • Among the EU5 countries, Germany has the maximum revenue share in 2021, while Spain has the lowest market share.

  • The total mortality-adjusted Incident Cases of AKI in the 7MM comprised 6,470,000+ cases in 2021.

  • The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.

  • Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021. 

Acute Kidney Injury (AKI) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Kidney Injury market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Acute Kidney Injury market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute kidney injury (AKI) Market Drivers

  • Robust Pipeline Activity

  • Reimbursement policies

  • Increased incidence of hospitalization

Acute Kidney Injury (AKI) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Acute kidney injury (AKI) Epidemiology Segmentation

  • Discharge Diagnosed Cases

  • Total Incident Patient Population

  • Risk Factor Associated AKI Cases

  • Stage-wise Discharged Diagnosed cases

  • Renal Transplantation Associated Delayed Graft Function Cases

Acute Kidney Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Kidney Injury market or expected to get launched during the study period. The analysis covers the Acute Kidney Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Kidney Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Acute Kidney Injury Market Will Evolve by 2032 @

Acute Kidney Injury (AKI) Therapeutics Analysis

Acute kidney injury (AKI) is frequently associated with poor outcomes, including increased mortality, a higher risk of chronic kidney disease, and prolonged hospital lengths of stay. Despite harmonization in clinical definition and staging, identification of novel renal biomarkers for clinical use, and progress in understanding the underlying pathophysiology, there remains a major unmet medical need.

Currently, the Acute Kidney Injury market persists with various unmet needs related to diagnosis and effective treatment, which include a lack of approved therapies and high affordability.

Some of the key companies in the Acute Kidney Injury (AKI) Market include:

  • Exponential Biotherapies

  • Alloksys

  • Angion Biomedica

  • Quark Pharmaceuticals

  • AM Pharma

  • AtoxBio

  • Astellas Pharma

  • Pharming Technologies

  • MediBeacon

  • Orion Pharma

And many others

Acute Kidney Injury (AKI) Therapies covered in the report include:

  • EA-230


  • ANG-3777 (BB3)

  • QPI-1002

  • recAP

  • Reltecimod

  • ASP1128

  • Ruconest (Conestat alfa)

  • MB-102

  • Levosimendan (Simdax)

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Kidney Injury Competitive Intelligence Analysis

4. Acute Kidney Injury Market Overview at a Glance

5. Acute Kidney Injury Disease Background and Overview

6. Acute Kidney Injury Patient Journey

7. Acute Kidney Injury Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Acute Kidney Injury Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Kidney Injury Unmet Needs

10. Key Endpoints of Acute Kidney Injury Treatment

11. Acute Kidney Injury Marketed Products

12. Acute Kidney Injury Emerging Drugs and Latest Therapeutic Advances

13. Acute Kidney Injury Seven Major Market Analysis

14. Attribute Analysis

15. Acute Kidney Injury Market Outlook (In US, EU5, and Japan)

16. Acute Kidney Injury Access and Reimbursement Overview

17. KOL Views on the Acute Kidney Injury Market

18. Acute Kidney Injury Market Drivers

19. Acute Kidney Injury Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Metastatic Uveal Melanoma (MUM) Market

“Metastatic Uveal Melanoma (MUM) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Metastatic Uveal Melanoma Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Leave a Reply

Your email address will not be published. Required fields are marked *